JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.30 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $650,000 | -93.1% | 14,218 | -93.2% | 0.01% | -92.4% |
| Q3 2017 | $9,436,000 | +44.1% | 210,373 | -3.9% | 0.18% | +25.0% |
| Q2 2017 | $6,546,000 | +35.0% | 219,018 | +0.2% | 0.15% | +25.4% |
| Q1 2017 | $4,848,000 | +19.1% | 218,504 | +1.1% | 0.12% | +28.3% |
| Q4 2016 | $4,072,000 | +703.2% | 216,051 | +1177.0% | 0.09% | +607.7% |
| Q3 2016 | $507,000 | +10.0% | 16,918 | +40.8% | 0.01% | -7.1% |
| Q2 2016 | $461,000 | +9.8% | 12,018 | +8.9% | 0.01% | +7.7% |
| Q1 2016 | $420,000 | -16.3% | 11,035 | -3.4% | 0.01% | -18.8% |
| Q4 2015 | $502,000 | -35.0% | 11,420 | -39.8% | 0.02% | -40.7% |
| Q3 2015 | $772,000 | -14.0% | 18,980 | +12.6% | 0.03% | -10.0% |
| Q2 2015 | $898,000 | +1660.8% | 16,855 | +1871.3% | 0.03% | +1400.0% |
| Q1 2015 | $51,000 | +82.1% | 855 | +55.5% | 0.00% | +100.0% |
| Q4 2014 | $28,000 | – | 550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |